{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:04:19Z","timestamp":1771380259998,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.cpcardiol.2026.103266","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:54:09Z","timestamp":1768413249000},"page":"103266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fabry disease cardiomyopathy: A practical guide for cardiologists"],"prefix":"10.1016","volume":"51","author":[{"given":"Tala","family":"Al Saleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf Kamran","family":"Qadeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim El","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiano de Oliveira","family":"Poswar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Vardarli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chayakrit","family":"Krittanawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103266_bib0001","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac involvement in Fabry Disease: JACC review topic of the week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0002","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience","volume":"190","author":"Burton","year":"2017","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-galactosidase A p.A143T, a non-fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0004","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157782","article-title":"Accumulation of \u03b1-synuclein mediates podocyte injury in Fabry nephropathy","volume":"133","author":"Braun","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0005","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120985627","article-title":"Renal Manifestations of Fabry Disease: a narrative review","volume":"8","author":"Silva","year":"2021","journal-title":"Can J Kidney Health Dis"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/WCO.0b013e32834a9433","article-title":"Fabry disease","volume":"24","author":"Toyooka","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0007","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Neurological manifestations of Fabry disease","author":"Schiffmann","year":"2006"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","article-title":"Pain management strategies for neuropathic pain in Fabry disease\u2013a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0009","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","article-title":"Cardiac valvular anomalies in Fabry disease. clinical, morphologic, and biochemical studies","volume":"54","author":"Desnick","year":"1976","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijcard.2008.04.075","article-title":"Clinical usefulness of tissue doppler imaging in predicting preclinical Fabry cardiomyopathy","volume":"132","author":"Toro","year":"2009","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.122.001250","article-title":"Mitochondrial microRNAs are dysregulated in patients with Fabry Disease","volume":"384","author":"Gambardella","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"18","key":"10.1016\/j.cpcardiol.2026.103266_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810088","article-title":"Pathogenesis and molecular mechanisms of Anderson-Fabry disease and possible new molecular addressed therapeutic strategies","volume":"22","author":"Tuttolomondo","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/eji.201545725","article-title":"Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner","volume":"46","author":"Pereira","year":"2016","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035182","article-title":"Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative","volume":"10","author":"Hughes","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0016","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2261-11-6","article-title":"Persistent increase in cardiac troponin I in Fabry disease: a case report","volume":"11","author":"Tanislav","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0017","article-title":"The utility of high-sensitivity troponin to detect cardiomyopathy in patients with Fabry disease","volume":"66","author":"Wanninayake","year":"2025","journal-title":"JIMD Rep"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157640","article-title":"Cardiac Troponin I: a valuable biomarker indicating the cardiac involvement in Fabry disease","volume":"11","author":"Tanislav","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0019","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/imj.70231","article-title":"Troponin rise in Fabry disease: an Australian perspective","volume":"55","author":"Kansal","year":"2025","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial edema, myocyte injury, and disease severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091757","article-title":"Continuous cardiac troponin I release in Fabry disease","volume":"9","author":"Feustel","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002839","article-title":"High-sensitivity troponin: a clinical blood biomarker for staging cardiomyopathy in Fabry Disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccep.2015.03.014","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"7","author":"Acharya","year":"2015","journal-title":"Card Electrophysiol Clin"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103266_bib0024","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/europace\/eul121","article-title":"Electrophysiological study in a patient with Fabry disease and a short PQ interval","volume":"8","author":"Jastrzebski","year":"2006","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0025","article-title":"ECG changes during adult life in Fabry Disease: results from a large longitudinal cohort study","volume":"13","author":"El Sayed","year":"2023","journal-title":"Diagn (Basel)"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0026","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002316","article-title":"Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease","volume":"10","author":"Vijapurapu","year":"2023","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0027","doi-asserted-by":"crossref","first-page":"201","DOI":"10.31083\/j.rcm2306201","article-title":"Echocardiography in Anderson-Fabry Disease","volume":"23","author":"Lillo","year":"2022","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0029","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0030","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry\u2019s disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0031","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamacardio.2017.2353","article-title":"Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy","volume":"2","author":"Cecchi","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0032","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/echo.14508","article-title":"Echocardiographic features of Fabry cardiomyopathy-comparison with hypertrophy-matched sarcomeric hypertrophic cardiomyopathy","volume":"36","author":"Militaru","year":"2019","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0033","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2006.07.088","article-title":"Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry\u2019s disease","volume":"99","author":"Kawano","year":"2007","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0034","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ejechocard\/jer112","article-title":"The endocardial binary appearance (\u2018binary sign\u2019) is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy","volume":"12","author":"Mundigler","year":"2011","journal-title":"Eur J Echocardiogr"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103266_bib0035","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.jacc.2005.11.070","article-title":"Fabry\u2019s Disease Cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization","volume":"47","author":"Pieroni","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0036","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"issue":"23","key":"10.1016\/j.cpcardiol.2026.103266_bib0037","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1136\/hrt.2010.204586","article-title":"The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy","volume":"96","author":"Niemann","year":"2010","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0038","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0039","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2009","journal-title":"Eur Heart J"},{"issue":"15","key":"10.1016\/j.cpcardiol.2026.103266_bib0041","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0042","article-title":"Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease","volume":"5","author":"Dan","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1440636","article-title":"Cardiac involvement in Anderson-Fabry disease. The role of advanced echocardiography","volume":"11","author":"Spinelli","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103266_bib0044","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in Fabry Disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0045","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/echo.13496","article-title":"Loss of base-to-apex circumferential strain gradient: a specific pattern of Fabry cardiomyopathy?","volume":"34","author":"Labombarda","year":"2017","journal-title":"Echocardiography"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103266_bib0046","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10554-020-01847-z","article-title":"Left ventricular radial strain impairment precedes hypertrophy in Anderson\u2013Fabry disease","volume":"36","author":"Spinelli","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0047","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/ehjci\/jey108","article-title":"Prominent longitudinal strain reduction of left ventricular basal segments in treatment-na\u00efve Anderson-Fabry disease patients","volume":"20","author":"Esposito","year":"2018","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103266_bib0048","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1540-8175.2012.01704.x","article-title":"Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy","volume":"29","author":"Gruner","year":"2012","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0049","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/echo.14592","article-title":"Mechanical dispersion in Fabry disease assessed with speckle tracking echocardiography","volume":"37","author":"Cianciulli","year":"2020","journal-title":"Echocardiography"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103266_bib0050","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1093\/eurheartj\/ehm454","article-title":"A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium","volume":"28","author":"Weidemann","year":"2007","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0051","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","article-title":"Impaired left atrial function in Fabry Disease: a longitudinal speckle-tracking echocardiography study","volume":"30","author":"Pichette","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0052","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/clc.23019","article-title":"Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study","volume":"41","author":"Di","year":"2018","journal-title":"Clin Cardiol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0053","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/echo.15224","article-title":"Comparative analysis of phasic left atrial strain and left ventricular posterolateral strain pattern to discriminate Fabry cardiomyopathy from other forms of left ventricular hypertrophy","volume":"38","author":"Frumkin","year":"2021","journal-title":"Echocardiography"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131357","article-title":"Left atrial remodeling in hypertrophic cardiomyopathy and Fabry disease: a CMR-based head-to-head comparison and outcome analysis","volume":"393","author":"Moroni","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2021.02.038","article-title":"Right ventricular strain in Anderson-Fabry disease","volume":"330","author":"Lillo","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0056","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2022.12.047","article-title":"Right ventricular strain in Fabry disease: prognostic implications","volume":"374","author":"Meucci","year":"2023","journal-title":"Int J Cardiol"},{"issue":"13","key":"10.1016\/j.cpcardiol.2026.103266_bib0057","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00259-017-3778-1","article-title":"Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease","volume":"44","author":"Imbriaco","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0058","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/ehjci\/jez062","article-title":"Unusual SPECT myocardial perfusion imaging results in the setting of ventricular hypertrophy and non-obstructive coronary artery disease should suggest Anderson-Fabry disease","volume":"20","author":"Djaileb","year":"2019","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0059","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/j.semnuclmed.2011.04.001","article-title":"Cardiac applications of 123I-mIBG imaging","volume":"41","author":"Chirumamilla","year":"2011","journal-title":"Semin Nucl Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00259-015-3273-5","article-title":"Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease","volume":"43","author":"Spinelli","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0061","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12350-019-01734-8","article-title":"Focal reduction in left ventricular (123)I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease","volume":"28","author":"Spinelli","year":"2021","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0062","first-page":"161","article-title":"Angina in Fabry disease reflects coronary small vessel disease","volume":"1","author":"Chimenti","year":"2008","journal-title":"Circ: Heart Fail"},{"issue":"19","key":"10.1016\/j.cpcardiol.2026.103266_bib0063","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194422","article-title":"Atherosclerosis in Fabry Disease-A contemporary review","volume":"10","author":"Roy","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0064","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1253\/circj.CJ-18-0734","article-title":"Unexpectedly high prevalence of coronary spastic angina in patients with Anderson-Fabry Disease","volume":"83","author":"Kitani","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","article-title":"Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease","volume":"18","author":"Deva","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0066","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diii.2019.08.006","article-title":"Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping","volume":"101","author":"Deborde","year":"2020","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0067","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0068","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1055\/a-0836-2723","article-title":"Assessment of cardiac involvement in Fabry disease (FD) with native T1 mapping","volume":"191","author":"Roller","year":"2019","journal-title":"Rofo"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0069","article-title":"The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patients","volume":"31","author":"Anan","year":"2022","journal-title":"Mol Genet Metab Rep"},{"issue":"8 Pt 2","key":"10.1016\/j.cpcardiol.2026.103266_bib0070","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jcmg.2018.03.020","article-title":"Proposed stages of myocardial phenotype development in Fabry disease","volume":"12","author":"Nordin","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103266_bib0071","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0072","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","article-title":"Atrial dysfunction assessed by Cardiac magnetic resonance as an early marker of Fabry cardiomyopathy","volume":"13","author":"Bernardini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0073","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0074","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"10.1016\/j.cpcardiol.2026.103266_bib0075","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJM200006153422403","article-title":"Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy","volume":"342","author":"Spirito","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0076","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/jmri.29700","article-title":"Left ventricular hemodynamic forces changes in Fabry disease: a cardiac magnetic resonance study","volume":"62","author":"Li","year":"2025","journal-title":"J Magn Reson Imaging"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0077","doi-asserted-by":"crossref","first-page":"91","DOI":"10.21037\/cdt-20-897","article-title":"Quantification of myocardial deformation in patients with Fabry disease by cardiovascular magnetic resonance feature tracking imaging","volume":"11","author":"Zhao","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0078","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13023-024-03396-3","article-title":"Evaluation of global and regional myocardial work by echocardiography in patients with Fabry disease","volume":"19","author":"Wang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0079","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/ehf2.14091","article-title":"Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations","volume":"9","author":"Rob","year":"2022","journal-title":"ESC Heart Fail"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103266_bib0080","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.echo.2024.04.010","article-title":"Prognostic implications of left ventricular hypertrophy and mechanical function in Fabry Disease: a longitudinal cohort study","volume":"37","author":"Chang","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0081","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/hrt.2004.035584","article-title":"The natural history of left ventricular systolic function in Anderson-Fabry disease","volume":"91","author":"Shah","year":"2005","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0082","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcu.23592","article-title":"Clinical study of left ventricular structure and function in patients with Anderson-Fabry disease before and after enzyme replacement therapy","volume":"52","author":"Huang","year":"2024","journal-title":"J Clin Ultrasound"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0083","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","article-title":"Right ventricular hypertrophy, systolic function, and disease severity in Anderson-Fabry Disease: an echocardiographic study","volume":"30","author":"Graziani","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"issue":"s447","key":"10.1016\/j.cpcardiol.2026.103266_bib0084","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1651-2227.2005.tb02104.x","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0085","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular Involvement in Fabry Disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0086","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0087","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11886-024-02053-2","article-title":"Arrhythmogenesis in Fabry Disease","volume":"26","author":"Roy","year":"2024","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0088","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s10554-020-01869-7","article-title":"Correlation of left atrial strain with left ventricular end-diastolic pressure in patients with normal left ventricular ejection fraction","volume":"36","author":"Fan","year":"2020","journal-title":"Int J Cardiovasc Imaging"},{"issue":"23","key":"10.1016\/j.cpcardiol.2026.103266_bib0089","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in Fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"10.1016\/j.cpcardiol.2026.103266_bib0091","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore","year":"2007","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0092","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kr\u00e4mer","year":"2014","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103266_bib0093","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson\u2013Fabry Disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132444","article-title":"Ventricular arrhythmias and primary prevention of sudden cardiac death in Anderson-Fabry disease","volume":"415","author":"Piccolo","year":"2024","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.echo.2021.09.013","article-title":"Burden of valvular heart disease in patients with Fabry disease","volume":"35","author":"Yogasundaram","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0096","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med Biol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0097","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","article-title":"Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients","volume":"63","author":"Senechal","year":"2003","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0098","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0002-9343(80)90224-7","article-title":"Chronic airflow obstruction in Fabry's disease","volume":"68","author":"Rosenberg","year":"1980","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.cpcardiol.2026.103266_bib0099","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen","year":"2013","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000226792","article-title":"Excessive daytime sleepiness is a common symptom in Fabry Disease","volume":"1","author":"Duning","year":"2009","journal-title":"Case Rep Neurol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2026.103266_bib0101","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.humpath.2011.09.020","article-title":"Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study","volume":"43","author":"Chimenti","year":"2012","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.cpcardiol.2026.103266_bib0102","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0000000000001333","article-title":"Thromboembolic events in Fabry disease and the impact of factor V Leiden","volume":"84","author":"Lenders","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.cpcardiol.2026.103266_bib0103","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","article-title":"Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson\u2013Fabry disease","volume":"15","author":"Tomberli","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103266_bib0104","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.008872","article-title":"Quantitative myocardial perfusion in Fabry Disease","volume":"12","author":"Knott","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2022.07.046","article-title":"Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease","volume":"369","author":"Graziani","year":"2022","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2026.103266_bib0106","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s12265-020-10097-2","article-title":"Screening of Fabry disease in patients with chest pain without obstructive coronary artery disease","volume":"14","author":"Hern\u00e1ndez-Hern\u00e1ndez","year":"2021","journal-title":"J Cardiovasc Transl Res"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0107","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0108","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"Kidney Disease: improving global outcomes\" (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","article-title":"The management and treatment of children with Fabry disease: a United States-based perspective","volume":"117","author":"Hopkin","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.cpcardiol.2026.103266_bib0110","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0111","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"issue":"7","key":"10.1016\/j.cpcardiol.2026.103266_bib0112","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.cpcardiol.2026.103266_bib0113","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0114","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry Disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Gu\u00e9rard","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.cpcardiol.2026.103266_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0117","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.cpcardiol.2026.103266_bib0118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.cpcardiol.2026.103266_bib0119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193550","article-title":"Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation","volume":"13","author":"Lavalle","year":"2018","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.cpcardiol.2026.103266_bib0120","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0121","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s13023-021-02150-3","article-title":"A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm","volume":"16","author":"Jefferies","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cpcardiol.2026.103266_bib0122","doi-asserted-by":"crossref","DOI":"10.2196\/55001","article-title":"Medical expert knowledge meets AI to enhance symptom checker performance for rare disease identification in Fabry disease: mixed methods study","volume":"4","author":"Pankow","year":"2025","journal-title":"Jmir ai"},{"issue":"1","key":"10.1016\/j.cpcardiol.2026.103266_bib0123","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-025-03655-x","article-title":"Applying artificial intelligence to rare diseases: a literature review highlighting lessons from Fabry disease","volume":"20","author":"Germain","year":"2025","journal-title":"Orphanet J Rare Dis"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280626000095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:25:41Z","timestamp":1771377941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280626000095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":123,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0146280626000095"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103266","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease cardiomyopathy: A practical guide for cardiologists","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2026.103266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103266"}}